Actavis plc, which is technically an Irish
company following the transfer of its headquarters to Dublin in 2013 for tax
purposes, is in advanced talks to acquire rival drug maker Forest Laboratories
Inc in a deal that could value Forest at up to $25bn, according to The Wall
The Journal says the deal is expected to be announced as early as Tuesday, its
contacts said. However, it also said that it's possible the talks could still
The newspaper says the proposed combination of the "Irish"-based Actavis and
Forest, of New York, is partly designed to position the resulting company to
deal with the changing health-care landscape in the US Hospitals, insurers and
doctors in the country are combining to make larger organizations that can
negotiate directly to buy prescription drugs.
A combined Actavis-Forest could offer a range of generic and brand-name
medicines, reaping economies of scale of its own.
Forest had a market capitalization of $19.3bn as of Friday's close, compared
with $33.4bn for Actavis.
Actavis is known for its generic drugs, but last year it bought Warner Chilcott,
an Irish provider of branded treatments for gastrointestinal and urological
Actavis plc is listed on the New Stock Exchange,
and it says while its global headquarters is located in Dublin, Ireland, its
administrative headquarters is based in Parsippany, New Jersey, USA.
Check out our
, at a low annual charge of €25